Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 open-label study of Preflucel seasonal trivalent influenza vaccine in adults and elderly participants
2009-011283-11Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Apr 2009
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label trial of cell culture-derived trivalent subunit influenza vaccine in influenza (2 arms), sponsored by Baxter International Inc. Primary endpoint: Seroconversion to each vaccine antigen at Day 21. Started Apr 2009; status: completed.
02
Drugs
cell culture-derived trivalent subunit influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2009-011283-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011283-11.